Pharmacological enhancement of behavioral therapy: focus on posttraumatic stress disorder
- PMID: 21309114
- DOI: 10.1007/7854_2009_10
Pharmacological enhancement of behavioral therapy: focus on posttraumatic stress disorder
Abstract
Improved efficacy in the treatment of posttraumatic stress disorder (PTSD) and other anxiety disorders is urgently needed. Traditional anxiety treatments of hypnosis and psychodynamic therapy may be of some help, but uncontrolled studies lead to inconclusive results on the efficacy of these treatment techniques. There is a larger literature supporting the efficacy of cognitive-behavioral procedures with PTSD, including prolonged exposure therapy, eye movement desensitization and reprocessing, and anxiety management techniques. The cutting-edge technology of virtual reality-based exposure therapy for PTSD is particularly exciting. To further build on effective psychosocial treatments, current pharmacological augmentation approaches to emotional learning are being combined with psychotherapy. In particular, D-cycloserine, a partial NMDA agonist, has shown to be effective in facilitating the exposure/extinction therapy to improve the efficacy of treating anxiety disorders, and may guide the way for new pharmacological enhancements of behavioral therapy.
Similar articles
-
Enhancing exposure-based therapy from a translational research perspective.Behav Res Ther. 2007 Sep;45(9):1987-2001. doi: 10.1016/j.brat.2007.06.006. Epub 2007 Jun 17. Behav Res Ther. 2007. PMID: 17659253 Free PMC article. Review.
-
Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear.Arch Gen Psychiatry. 2004 Nov;61(11):1136-44. doi: 10.1001/archpsyc.61.11.1136. Arch Gen Psychiatry. 2004. PMID: 15520361 Clinical Trial.
-
Randomized placebo-controlled D-cycloserine with cognitive behavior therapy for pediatric posttraumatic stress.J Child Adolesc Psychopharmacol. 2014 Mar;24(2):69-77. doi: 10.1089/cap.2013.0106. Epub 2014 Feb 7. J Child Adolesc Psychopharmacol. 2014. PMID: 24506079 Free PMC article. Clinical Trial.
-
[Virtual reality exposure therapy for post-traumatic stress disorders, obsessive-compulsive disorders and anxiety disorders: Indications, added value and limitations].Encephale. 2020 Aug;46(4):293-300. doi: 10.1016/j.encep.2020.01.005. Epub 2020 Mar 6. Encephale. 2020. PMID: 32151452 Review. French.
-
A Meta-Analysis of D-Cycloserine in Exposure-Based Treatment: Moderators of Treatment Efficacy, Response, and Diagnostic Remission.J Clin Psychiatry. 2017 Feb;78(2):196-206. doi: 10.4088/JCP.15r10334. J Clin Psychiatry. 2017. PMID: 27314661 Free PMC article.
Cited by
-
Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment.Pharmacol Ther. 2011 Dec;132(3):314-32. doi: 10.1016/j.pharmthera.2011.09.006. Epub 2011 Sep 22. Pharmacol Ther. 2011. PMID: 21963369 Free PMC article. Review.
-
From antipsychotic to anti-schizophrenia drugs: role of animal models.Trends Pharmacol Sci. 2012 Oct;33(10):515-21. doi: 10.1016/j.tips.2012.06.006. Epub 2012 Jul 16. Trends Pharmacol Sci. 2012. PMID: 22810174 Free PMC article.
-
Targeting memory processes with drugs to prevent or cure PTSD.Expert Opin Investig Drugs. 2012 Sep;21(9):1323-50. doi: 10.1517/13543784.2012.704020. Epub 2012 Jul 27. Expert Opin Investig Drugs. 2012. PMID: 22834476 Free PMC article. Review.
-
Pharmacological enhancement of mGluR5 facilitates contextual fear memory extinction.Learn Mem. 2014 Nov 17;21(12):647-50. doi: 10.1101/lm.035857.114. Print 2014 Dec. Learn Mem. 2014. PMID: 25403451 Free PMC article.
-
Reversal of Stress-Induced Social Interaction Deficits by Buprenorphine.Int J Neuropsychopharmacol. 2018 Feb 1;21(2):164-174. doi: 10.1093/ijnp/pyx079. Int J Neuropsychopharmacol. 2018. PMID: 29020387 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical